CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Denali Therapeutics Initiates a Phase 2 Study for the RIPK1 Inhibitor DNL758 (SAR443122) in Patients with Cutaneous Lupus Erythematosus (CLE)

Life Sciences Review Life Sciences Review | Monday, July 05, 2021
Tweet

Denali Therapeutics partners with Sanofi.


FREMONT, CA: Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad pipeline of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, collaborates with Sanofi. Their partnership begins dosing patients with cutaneous lupus erythematosus in a Phase 2 study of DNL758 (SAR443122), a peripherally restricted small molecule inhibitor of RIPK1 (CLE).


“We are delighted that our collaborators at Sanofi are advancing DNL758 into a Phase 2 study in patients with CLE and are excited about the potential of bringing a life-changing therapy to patients through our partnership,” says Ryan Watts Ph.D., Denalis Chief Executive Officer.


In October 2018, Denali and Sanofi announced a broad collaboration for the global development and commercialization of RIPK1 inhibitors. 


This includes peripherally restricted molecules such as DNL758 and CNS-permeable molecules such as DNL788 (SAR443820), which is currently being evaluated in healthy volunteers in a Phase 1 study for the potential development of neurological indications such as amyotrophic lateral sclerosis, multiple sclerosis, and Alzheimer's disease. Denali will receive a $15 million milestone payment from Sanofi in connection with the Phase 2 study with DNL758. Sanofi is responsible for the development and commercialization of DNL758 and is financially responsible for all associated costs. Denali is entitled to receive milestone payments for product development, regulatory approval, and sales, as well as royalties on product sales.


RIPK1 is an essential signaling protein in the tumor necrosis factor (TNF) receptor pathway that plays a role in inflammation and cell death regulation. CLE is a type of interface dermatitis characterized by immune cell infiltration, and inhibiting RIPK1 activity is a novel strategy for modulating CLE pathophysiology. Additional information about the Phase 2 clinical study of DNL758 for CLE (NCT04781816) can be found on the ClinicalTrials.gov website.


Weekly Brief

loading
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/denali-therapeutics-initiates-a-phase-2-study-for-the-ripk1-inhibitor-dnl758-sar443122-in-patients-with-cutaneous-lupus-erythematosus-cle-nwid-436.html